| alrizomadlin (APG-115) / Ascentage Pharma |
NCT04496349: A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL |
|
|
| Recruiting | 2 | 78 | US | APG-115, APG-2575 | Ascentage Pharma Group Inc. | T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | 05/26 | 05/27 | | |
NCT06654050: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma |
|
|
| Not yet recruiting | 2 | 15 | US | alrizomadlin | National Cancer Institute (NCI) | Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies | 12/27 | 12/27 | | |
Keynote MK-3475-B66, NCT03611868: A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 230 | US, RoW | Phase 1b: APG-115+pembrolizumab, KEYTRUDA® | Ascentage Pharma Group Inc., Merck Sharp & Dohme LLC | Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation, MDM2 Gene Mutation, Cutaneous Melanoma, Mucosal Melanoma, Malignant Peripheral Nerve Sheath Tumors (MPNST) | 12/24 | 03/25 | | |
NCT04358393: A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS |
|
|
| Recruiting | 1/2 | 69 | US | APG-115, 5-azacitidine, Vidaza, Azadine | Ascentage Pharma Group Inc. | AML, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, CMML, Myelodysplastic Syndromes, High-risk Myelodysplastic Syndrome, MDS | 12/24 | 12/25 | | |
NCT04785196: APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 95 | RoW | APG-115, Toripalimab | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Liposarcoma, Advanced Solid Tumor | 04/26 | 01/27 | | |
| Active, not recruiting | 1/2 | 41 | US | APG-115, Carboplatin | University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc. | Malignant Salivary Gland Cancer, Salivary Gland Cancer | 06/25 | 12/25 | | |
MEKMDM2, NCT06735820: Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST |
|
|
| Not yet recruiting | 1/2 | 45 | US | APG-115, alrizomadlin, Selumetinib, koselugo | AeRang Kim, Children's National Research Institute | Malignant Peripheral Nerve Sheath Tumor (MPNST), Neurofibromatosis 1 (NF1), Atypical Neurofibroma | 10/27 | 10/28 | | |
APG-115-AC101, NCT04275518: A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. |
|
|
| Recruiting | 1 | 102 | RoW | APG-115, Azacitidine, Cytarabine | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) | 12/25 | 12/25 | | |
NCT05701306: APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors |
|
|
| Recruiting | 1 | 100 | RoW | APG-115, APG-2575 | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Neuroblastoma, Solid Tumor | 06/26 | 12/27 | | |
